• Haemonetics will hold its annual shareholder meeting in Boston on July 24, 2026.
• Shareholders will vote to elect eight directors to one-year terms expiring in 2027.
• Items include an advisory vote on named executive officer pay, plus ratification of Ernst & Young as auditor for fiscal 2027.
• Investors will also vote on amended and restated versions of the 2019 long-term incentive plan, plus the 2007 employee stock purchase plan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Haemonetics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000313143-26-000074), on June 09, 2026, and is solely responsible for the information contained therein.